RecruitingHepatocellular Carcinoma

A Trial Utilizing 18F-FS PG PET to Guide Therapy in Hepatocellular Carcinoma

Eligible age

18+ yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

To evaluate the relationship between 18F-FSPG uptake in HCC lesions, ctDNA in blood and clinical response to Y90 radioembolization therapy in patients with hepatocellular carcinoma (HCC) by SOC imaging.

Sponsor: M.D. Anderson Cancer Center

You may qualify if…

✓ 1. Diagnosis of HCC with one or more of the following:
✓ 1. Liver mass with non-rim arterial phase hyperenhancement (APHE) and one of the following:
✓ 1. 10-19 mm with ≥ 2 additional major features according to LI-RADS criteria ("washout", enhancing "capsule", and/or threshold growth),
✓ 2. 10-19 mm with "washout" and visibility at antecedent ultrasound (US) but with no "capsule" or threshold growth,
✓ 3. 10-19 mm with ≥50% size increase in ≤6 months but with no "washout" or "capsule" or
✓ 4. ≥20 mm with ≥1 additional major feature according to LI-RADS criteria ("washout", enhancing "capsule", or threshold growth).
✓ 2. Lesions that meet LI-RADS 4 criteria or
✓ 3. Lesions that meet LI-RADS 5 criteria or

You may not qualify if…

✕ 1. Patients under the age of 18 will be excluded from the this study.
✕ 2. Patients who have HCC but are not candidates for Y90 radioembolization monotherapy.
✕ 3. Pregnant and breastfeeding patients. Pregnant women are excluded from this study because 18F-FSPG as a radiotracer has a potential teratogenic or abortifacient effect. Because there is an unknown but potential risk for adverse events in nursing infants secondary to administration of the tracer 18F-FSPG to the mother, breastfeeding should be discontinued.
✕ 4. Patients with poorly controlled diabetes mellitus (fasting blood glucose level \> 200 mg/dL).
✕ 5. Patients with psychiatric illness/social situations that would limit compliance with study requirements.
✕ 6. Patients who have not recovered from AEs or had allergic reactions to similar compounds should be excluded.

Where it's recruiting

Texas

Houston

Source: ClinicalTrials.gov · NCT07116486 · last updated 2026-06-10